Moreover, patients with refractory primary central nervous system lymphoma (PCNSL) have achieved long-term complete remission following treatment with CD19/CD22 dual-targeting CAR-T cells in combination with PD-1 and BTK inhibitors 146. This evidence concerns the gene CD19 and primary central nervous system lymphoma.